• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Cholera - Pipeline Review, H2 2012 Product Image

Cholera - Pipeline Review, H2 2012

  • Published: September 2012
  • 40 pages
  • Global Markets Direct

Cholera – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Cholera - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cholera, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cholera. Cholera - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cholera.
- A review of the Cholera products under development by companies and universities/research institutes based on information derived from company and industry-specific READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Cholera Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Cholera 7
Cholera Therapeutics under Development by Companies 9
Cholera Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Cholera Therapeutics – Products under Development by Companies 15
Cholera Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Cholera Therapeutics Development 17
Napo Pharmaceuticals, Inc. 17
Vaccine Technologies, Inc. 18
PaxVax 19
Cholera – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
crofelemer - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Peru-15 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Bivalent Killed Oral Cholera Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Cholera Toxin B - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Dukoral Vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
PXVX-0200 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Cholera Therapeutics – Drug Profile Updates 32
Cholera Therapeutics - Dormant Products 35
Cholera – Product Development Milestones 36
Featured News & Press Releases 36
Mar 19, 2012: FDA Accepts PaxVax’s IND For Single-Dose Oral Cholera Vaccine 36
Aug 26, 2008: Crucell to move Dukoral and rCTB bulk production, formulation and fill/finish activities from Sweden to other sites 36
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 37
Feb 25, 2003: Dukoral Approved In Canada 38
Mar 11, 2002: European Marketing Authorisation Application Submitted For Dukoral 38
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables
Number of Products Under Development for Cholera, H2 2012 7
Products under Development for Cholera – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Napo Pharmaceuticals, Inc., H2 2012 17
Vaccine Technologies, Inc., H2 2012 18
PaxVax, H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 24
Cholera Therapeutics – Drug Profile Updates 32
Cholera Therapeutics – Dormant Products 35

List of Figures
Number of Products under Development for Cholera, H2 2012 7
Products under Development for Cholera – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 20
Assessment by Route of Administration, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 22
Assessment by Molecule Type, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 24

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos